News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Four into one for new HIV TREATMENT

Media release                                                            Thursday, December 21 2006

Four into one for new HIV TREATMENT

People taking four tablets a day for HIV will soon only need to take one, following a funding decision by PHARMAC

In the latest decision concerning HIV medicines, the government drug-buying agency will fund fixed-dose abacavir and lamivudine (Kivexa) from January 1, 2007. Kivexa is a combination of two medicines that are already subsidised for people with HIV.

PHARMAC estimates that nearly 250 patients will find it more convenient to take their medicine as a result of the decision.

PHARMAC’s deputy medical director Dr Dilky Rasiah says that currently, the people with HIV being treated with abacavir and lamivudine need to take four pills a day. From 1 January, that will change to just one pill once a day.

“The change will mean treatment is easier for patients, prescribing is easier for doctors and dispensing is easier for pharmacists,” she says.

“This means it will be easier for people to take their medicine properly, which is important in combination HIV therapy to avoid drug resistance.”

Standard treatment with HIV is to use combination therapy with three or more antiretroviral drugs.

There are no differences between the effect of the combined and separate forms of abacavir and lamivudine, Dr Rasiah says.

As well as helping people with HIV, the decision is also expected to produce cost savings for District Health Boards, as the combination pill is cheaper than the individual medications.  Savings are estimated at nearly $1.5 million over five years.

There are approximately 1,300 people diagnosed with Human Immuno-deficiency Virus (HIV) in New Zealand. Of these, about 700 people are receiving antiretroviral therapy.


PHARMAC currently funds four classes of antiretroviral drugs. Most recently, PHARMAC has approved funding for a new class of drug (Fuzeon) and for a new type of protease inhibitor (Reyataz).












© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


Howard Davis: Review - A Girl Named Mo

Moana Ete brought her three-piece band A Girl Named Mo to Wellington's intimate and iconic Bats Theatre last week for a five-night residency. Each show was recorded and filmed live for the release of her debut album 'Platonic/Romantic' on Loop records later this year. More>>

For The Birds: Who Will Be Crowned Bird Of The Year?

The competition involves well-known and enthusiastic New Zealanders acting as ‘campaign managers’ for their favourite birds with many going to great lengths to get New Zealanders to vote for their chosen bird... More>>


  • Image Out-Link - Giselle Clarkson on Twitter
  • Gordon Campbell: On Bob Dylan's Nobel (And The Surplus)

    So Bob Dylan has just won the Nobel Prize for… Literature? Wow. I’d be just as happy if he’d won for his work on particle physics (“One Grain of Sand”, “Simple Twist of Fate”) or got the Economics prize for his work on the theory of contracting (“Don’t Think Twice Its Alright”) ... More>>


    Scoop Review Of Books: Whose Goat Was That?

    Mysterious Mysteries of Aro Valley is a sharp, satirical and sometimes downright scary romp through and around that valley in ways that made me question the realities of the places I thought I knew so well. More>>


    NZ On Air TV Funding: More Comedy Comes Out Of The Shadows

    Paranormal Event Response Unit is a series conceived by Jemaine Clement and Taika Waititi as a TV spin-off from their highly acclaimed feature film What We Do In The Shadows. More>>


    Mars News: Winners Announced For The 2016 Apra Silver Scroll Awards

    Wellington singer-songwriter and internationally acclaimed musician Thomas Oliver has won the 2016 APRA Silver Scroll Award with his captivating love song ‘If I Move To Mars’. More>>


    Get More From Scoop



    Search Scoop  
    Powered by Vodafone
    NZ independent news